Collegium Pharmaceutical, Inc
A pharmaceutical company making medicines for pain and ADHD, including the opioid painkiller Xtampza ER (built on its DETERx abuse-deterrent technology), Belbuca, the Nucynta products, and Jornay PM, an evening-dosed ADHD stimulant. Founded in 2002 by Michael Heffernan to develop safer opioids, its name comes from the Latin "collegium," meaning a band of colleagues working together. The company even named its technology DETERx — a nod to deterring misuse, which is why its microsphere-in-capsule pain pills are hard to crush or inject.
Sold 25.0K
Granted 907.1K · Sold 439.0K
Granted 73.8K · Sold 22.4K
Granted 217.8K
Granted 323.7K · Sold 108.2K
Granted 43.0K
Granted 73.8K · Sold 5.4K
Granted 384.6K · Sold 263.1K
Granted 76.2K · Sold 34.9K
Granted 142.7K · Sold 28.1K
Granted 99.6K · Sold 20.2K
Granted 435.2K · Sold 321.9K
Granted 87.7K · Sold 37.7K
Granted 50.1K · Sold 3.6K
Granted 31.5K
Granted 335.0K · Sold 298.6K
Granted 49.4K
Granted 28.3K
Granted 31.3K · Sold 4.5K
Granted 17.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rosen David Efraim +1 co-filer10% owner · 1 transaction | — | 6.29Mas of Aug 2025 | — | — | 25.0K |
| Ciaffoni JosephPresident and CEO, Director · 47 transactions | +98.6% | 526.3Kas of Feb 2024 | 907.1K | — | 439.0K |
| Freund John GordonDirector · 11 transactions | — | 195.0K | 73.8K | — | 22.4K |
| Karnani VikramPresident and CEO, Director · 5 transactions | — | 176.6K | 217.8K | — | — |
| Tupper ColleenEVP & Chief Financial Officer · 31 transactions | — | 147.3K | 323.7K | — | 108.2K |
| Malamut RichardEVP and Chief Medical Officer · 4 transactions | +39.3% | 130.3Kas of Feb 2022 | 43.0K | — | — |
| Santini GinoDirector · 8 transactions | +154.9% | 112.5K | 73.8K | — | 5.4K |
| Kuhlmann Shirley R.EVP and General Counsel · 37 transactions | +20.2% | 108.1Kas of Mar 2025 | 384.6K | — | 263.1K |
| Fallon John A.Director · 7 transactions | +326.6% | 99.5K | 76.2K | — | 34.9K |
| Smith Thomas BEVP and Chief Medical Officer · 16 transactions | — | 85.3K | 142.7K | — | 28.1K |
| Dieter DavidEVP & General Counsel · 7 transactions | — | 77.1K | 99.6K | — | 20.2K |
| Dreyer ScottEVP & Chief Commercial Officer · 50 transactions | -8.9% | 75.3K | 435.2K | — | 321.9K |
| Bohlin Garen GDirector · 9 transactions | +238.9% | 71.0K | 87.7K | — | 37.7K |
| Balice-Gordon Rita J.Director · 6 transactions | +310% | 61.4K | 50.1K | — | 3.6K |
| Melincoff Gwen ADirector · 3 transactions | +150.5% | 52.5Kas of May 2024 | 31.5K | — | — |
| Heffernan Michael ThomasDirector · 26 transactions | +259.8% | 50.3Kas of Feb 2025 | 335.0K | — | 298.6K |
| McFarlane Neil F.Director · 4 transactions | — | 49.4Kas of May 2024 | 49.4K | — | — |
| Paya Carlos VDirector · 2 transactions | — | 28.3K | 28.3K | — | — |
| Lurker NancyDirector · 4 transactions | — | 26.8K | 31.3K | — | 4.5K |
| Glancy Donovan MichaelDirector · 1 transaction | — | 17.5K | 17.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.61M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.